Todd Campbell
XMFEBCapital
Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.
Recent Articles by Todd Campbell
Oct 11, 2016
by Todd Campbell
How DexCom Can Fight Back Against Medtronic's Artificial Pancreas
The approval of Medtronic's Minimed 670G could reshape the type 1 treatment market next year, but I wouldn't count DexCom out. Its best-in-class technology could position it to capture a significant share of the artificial pancreas market in the future.
Sep 29, 2016
by Todd Campbell and Kristine Harjes
One Biotech Crashes, the Other Skyrockets -- Here's Why
Hit-or-miss data, delays, and contentious debate preceded the FDA's green-lighting of the first drug to target the cause of Duchenne muscular dystrophy. Meanwhile, a disappointing data readout stops one vaccine maker in its tracks.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.